A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Gibson, MD
Eastern Cooperative Oncology Group
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Michigan
Ann Arbor, Michigan, United States
- Case Western Reserve University
Cleveland, Ohio, United States
- Upmc / Upmc Cancer Centers
Pittsburgh, Pennsylvania, United States
- University of Texas Md Anderson
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2006
- Primary completion
- 29 Feb 2012
- Completion
- 29 Feb 2012
- Last update posted
- 20 Oct 2017
- Registered enrollment
- 48
- Registry id
- NCT00409565
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.